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Generally, adherence to guideline recommendations is poorly studied. Aben et al. [1] have focused on adherence to guideline recommendation for management of clinical T1 renal cancers in the Netherlands. In this populationbased study, the implications of national and international guidelines are well evaluated and provide insight on how adherence to guidelines could be compared across different health care systems in Europe. No recommendations can be given for targeted therapy to improve outcome after metastasectomy. This clinical scenario has been evaluated by Brehmer et al. [2] when presenting their data on resection of metastasis and local recurrences of RCC after The guest editors of this special issue, all members of the European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel, have been asked by the editorial board of the World Journal of Urology to collect and publish a series of articles on RCC which touch on topics for which high level of evidence recommendations are lacking 1 3 presurgical targeted therapy. We hope to have drawn your interest in including some topics of our own groups [3] [4] [5] on comparison of prognostic risk models in patients with synchronous metastatic RCC treated in the era of targeted therapy and surgical options in metastatic disease as well as the probability of RCC recurrence in a Swedish populationbased study. Due to a lack of comparative data on different follow-up schedules, no clear recommendations for surveillance can be given in guidelines. We are therefore pleased to add to the Swedish data on recurrence further follow-up studies from Norway [6] and the Netherlands [4] .
The guest editors of this issue of the World Journal of Urology are thankful to have the opportunity to draw attention to the third most frequent urological malignancy. We wish our readers an inspiring and interesting time reading the following articles on the latest controversies on renal cell carcinoma.
